
FDA Commissioner’s National Priority Voucher program reportedly in limbo for expedited drug reviews.
An FDA advisory panel voted to recommend six of seven unapproved peptides for compounding access, raising concerns about its newly appointed members.
In a two-day meeting that exposed deep fault lines, an FDA advisory committee voted to recommend that compounding pharmacies be allowed to manufacture six of seven unapproved peptides under review.






